NCT06711978View on ClinicalTrials.gov

Comparison of the Efficacy and Safety of Mirogabalin and Duloxetine in Chemotherapy-induced Peripheral Neuropathy in a Randomized Controlled Trial: a Quality of Life Study in Cancer Survivors

NANot yet recruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

May 31, 2025

Study Completion Date

June 30, 2025

Conditions
CIPNCIPN - Chemotherapy-Induced Peripheral NeuropathyCIPN in Adjuvant Breast Cancer PatientsDuloxetineMirogabalin
Interventions
DRUG

Mirogabalin

Participants will receive Mirogabalin at a dose of twice daily for 4 weeks to manage CIPN pain.

DRUG

Duloxetine

Participants will receive Duloxetine at a dose of once daily for 4 weeks to manage CIPN pain.

Trial Locations (1)

50612

Yangsan Pusan National University Hospital, Mulgeum

All Listed Sponsors
lead

Pusan National University Yangsan Hospital

OTHER

NCT06711978 - Comparison of the Efficacy and Safety of Mirogabalin and Duloxetine in Chemotherapy-induced Peripheral Neuropathy in a Randomized Controlled Trial: a Quality of Life Study in Cancer Survivors | Biotech Hunter | Biotech Hunter